In-house HIV-1 RNA real-time RT-PCR assays: Principle, available tests and usefulness in developing countries

Expert Review of Molecular Diagnostics

Volumn 8, Issue 5, 2008, Pages 635-650

  Rouet, François ^a   Ménan, Hervé ^b   Viljoen, Johannes ^c   Ngo Giang Huong, Nicole ^d   Mandaliya, Kishor ^e   Valéa, Diane ^a   Truong, Xuan Lien ^f   Danaviah, Sivapragashini ^c   Rousset, Dominique ^g   Ganon, Amandine ^h   Nerrienet, Eric ⁱ  

^a CENTRE MURAZ   (Burkina Faso)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e Department of Obstetrics and Gynaecology   (Kenya)

^f PASTEUR INSTITUTE   (Viet Nam)

^g CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

Developing country; Genetic diversity; HIV 1; PCR; Quantitative; Real time; Reverse transcription; RNA; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CYANINE DYE; DNA DIRECTED RNA POLYMERASE; GAG PROTEIN; INTERCALATING AGENT; PRIMER RNA; VIRUS RNA;

ACCURACY; BIOCHEMISTRY; DEVELOPING COUNTRY; DRUG EFFICACY; FLUORESCENCE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYBRIDIZATION; HYDROLYSIS; INFECTION PREVENTION; LICENSING; MOLECULAR PROBE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; STANDARDIZATION; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

EID: 51849156945     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.5.635     Document Type: Review

References (104)

1. Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
2. Peter JB, Sevall-Sanders J. Molecular-based methods for quantifying HIV viral load. AIDS Patient Care STDS 18, 75-79 (2004).
3. Wittek M, Stürmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev. Mol. Diagn. 7, 237-246 (2007).
4. Mellors JW, Margolick JB, Phair JP et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 297(21), 2349-2350 (2007).
5. Shearer WT, Quinn TC, LaRussa P et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N. Engl. J. Med. 336, 1337-1342 (1997).
6. Delamare C, Burgard M, Mayaux MJ et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. J. Acquir. Immune Defic. Syndr. 15, 121-125 (1997).
7. Blattner WA, Oursler KA, Cleghorn F et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J. Infect. Dis. 189(10), 1793-1801 (2004).
8. Polis MA, Sidorov IA, Yoder C et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 358(9295), 1760-1765 (2001).
9. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 21(Suppl. 4), S5-S10 (2007).
10. Calmy A, Ford N, Hirschel B et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin. Infect. Dis. 44(1), 128-134 (2007). • First review clearly demonstrating the clinical need for viral load testing in developing countries.
11. Fiscus SA, Cheng B, Crowe SM et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 3(10), e417 (2006).
12. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin. Lab. 53(3-4), 135-148 (2007).
13. Rouet F, Rouzioux C. HIV-1 viral load testing cost in developing countries: what's new? Expert Rev. Mol. Diagn. 7, 703-707 (2007). • Proposes different strategies for an expanded access to HIV-1 viral load measurements in resource-limited settings according to three expected requirement levels.
14. Elbeik T, Dalessandro R, Loftus RA, Beringer S. HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep (R)/TaqMan (R) test. Expert Rev. Mol. Diagn. 7(6), 723-753 (2007). • Significant paper that describes models to assess cost per reportable result for HIV-1 RNA viral load.
15. Bonard D, Rouet F, Toni TA et al. Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1CRF02_AG strains in Cote d'Ivoire, West Africa. J. Acquir. Immune Defic. Syndr. 34, 267-273 (2003).
16. Malmsten A, Shao XW, Sjodahl S et al. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J. Med. Virol. 76, 291-296 (2005).
17. Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomenclature proposal. Science 288, 55-56 (2000).
18. Powell RL, Zhao J, Konings FA et al. Circulating recombinant form (CRF) 37_cpx: an old strain in Cameroon composed of diverse genetically distant lineages of subtypes A and G. AIDS Res. Hum. Retrovirus 23, 923-933 (2007).
19. Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, vaccine development and trials. AIDS 17, 2547-2560 (2003).
20. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY), 10, 413-417 (1992).
21. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR: real time monitoring of DNA amplification reactions. Biotechnology (NY) 11, 1026-1030 (1993).
22. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl Acad. Sci. USA 88, 7276-7280 (1991).
23. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25(2), 169-193 (2000).
24. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol. 29, 23-39 (2002).
25. Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J. Biomol. Tech. 15, 155-166 (2004).
26. Bustin SA, Benes V, Nolan T, Pfaffl MW. Quantitative real-time RT-PCR - a perspective. J. Mol. Endocrinol. 34, 597-601 (2005).
27. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin. Sci. (Lond.) 109, 365-379 (2005).
28. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques 39, 75-85 (2005). • In-depth review of real-time PCR technologies.
29. Niesters HG. Quantitation of viral load using real-time amplification techniques. Methods 25(4), 419-429 (2001).
30. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 1, 1559-1582 (2006).
31. Kubista M, Andrade JM, Bengtsson M et al. The real-time polymerase chain reaction. Mol. Aspects Med. 27, 95-125 (2006). • In-depth review of real-time PCR technologies.
32. Vet JAM, Majithia AR, Marras SAE et al. Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc. Natl Acad. Sci. USA 96, 6394-6399 (1999).
33. -DD CT method. Methods 25, 402-408 (2001).
34. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
35. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal. Biochem. 302, 52-59 (2002).
36. Lalam N. Estimation of the reaction efficiency in polymerase chain reaction. J. Theor. Biol. 242, 947-953 (2006).
37. Kontanis EJ, Reed FA. Evaluation of real-time PCR amplification. Efficiencies to detect PCR inhibitors. J. Forensic Sci. 51, 795-804 (2006).
38. Pasloske BL, Walkerpeach CR, Obermoeller RD, Winkler M, Dubois DB. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J. Clin. Microbiol. 36, 3590-3594. (1998).
39. Akane A, Matsubara H, Nakamura S, Takahashi S, Kimura K. Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstrains, a major inhibitor of polymerase chain reaction (PCR) amplification. J. Forensic Sci. 39, 362-372 (1994).
40. Al-Soud WA, Jonsson LJ, Radström P. Identification and characterization of immunoglobulin G in blood as major inhibitor of diagnostic PCR. J. Clin. Microbiol. 38, 345-350 (2000).
41. Al-Soud WA, Radström P. Purification and characterization of PCR-inhibitory components in blood cells. J. Clin. Microbiol. 39, 485-493 (2001).
42. Izraeli S, Pfleiderer C, Lion T. Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood. Nucleic Acids Res. 19, 6051 (1991).
43. Lekanne-Deprez RH, Fijnvandraat AC, Ruijter JM, Moorman AF. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depend on cDNA systhesis conditions. Anal. Biochem. 307, 63-69 (2002).
44. Bernard PS, Wittwer CT. Homogeneous amplification and variant detection by fluorescent hybridization probes. Clin. Chem. 46, 147-148 (2000).
45. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 6, 995-1001 (1996).
46. Heid CA, Stevens J, Livak KJ, Williams PM. Real-time quantitative PCR. Genome Res. 6, 986-994 (1996).
47. Afonina I, Zivarts M, Kutyavin I et al. Efficient priming of PCR with short nucleotides conjugated to a minor groove binder. Nucleic Acids Res. 25, 2657-2660 (1997).
48. Weusten JJ, Carpay WM, Oosterlaken TA, van Zuijlen MC, van de Wiel PA. Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res. 30, e26 (2002).
49. Solinas A, Brown LJ, McKeen C et al. Duplex Scorpion primers in SNP analysis and FRET applications. Nucleic Acids Res. 29, E96 (2001).
50. Nazarenko I, Lowe B, Darfler M et al. Multiplex quantitative PCR using self-quenched primers labeled with a single fluorophore. Nucleic Acids Res. 30, e37 (2002).
51. Nazarenko IA, Bhatnagar SK, Hohman RJ. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res. 25, 2516-2521 (1997).
52. Gueudin M, Damond F, Braun J et al. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients. AIDS 22(2), 211-215 (2008).
53. Damond F, Collin G, Descamps D et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J. Clin. Microbiol. 43, 4234-4236 (2005).
54. Liu WC, Phiet PH, Chiang TY et al. Five subgenotypes of hepatitis B virus genotype B with distinct geographic and virological characteristics. Virus Res. 129(2), 212-223 (2007).
55. Halfon P, Bourliere M, Penaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J. Clin. Microbiol. 44(7), 2507-2511 (2006).
56. Nagot N, Foulongne V, Becquart P et al. Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women. J. Acquir. Immune Defic. Syndr. 39, 632-634 (2005).
57. Dehee A, Cesaire R, Desire N et al. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J. Virol. Methods 102(1-2), 37-51 (2002).
58. Leruez-Ville M, Ouachee M, Delarue R et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J. Clin. Microbiol. 41, 2040-2046 (2003).
59. Brengel-Pesce K, Morand P, Schmuck A et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J. Med. Virol. 66(3), 360-369 (2002).
60. Lefevre J, Hankins C, Pourreaux K, Voyer H, Coutlee F. Real-time PCR assays using internal controls for quantitation of HPV-16 and beta-globin DNA in cervicovaginal lavages. J. Virol. Methods 114(2), 135-144 (2003).
61. Gibellini D, Vitone F, Gori E, La Place M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. J. Virol. Methods 115(2), 183-189 (2004).
62. Gibellini D, Gardini F, Vitone F et al. Simultaneous detection of HCV and HIV-1 by SYBR Green real time multiplex RT-PCR technique in plasma samples. Mol. Cell Probes 20, 223-229 (2006).
63. Palmer S, Wiegand AP, Maldarelli F et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41(10), 4531-4536 (2003).
64. Shapshak P, Duncan R, McCoy CB, Page JB. Quantification of HIV gag RNA using real time reverse transcriptase PCR. Front. Biosci. 10, 135-142 (2005).
65. Watanaveeradej V, Sirirattanaphoomee S, Chantratita W et al. Quantification of HIV-1 RNA load by one-tube-one-step and real time PCR assay with TaqMan probe. J. Med. Assoc. Thai. 88, S206-S213 (2005).
66. Huang J, Yang CM, Wang LN et al. A novel real-time multiplex reverse transcriptase-polymerase chain reaction for the detection of HIV-1 RNA by using dual-specific armored RNA as internal control. Intervirology 51(1), 42-49 (2008).
67. Promso S, Srichunrusami C, Utid K et al. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by real-time RT-PCR assay using self-quenched fluorogenic primers. Southeast Asian J. Trop. Med. Public Health 37, 477-487 (2006).
68. Rekhviashvili N, Stevens G, Scott L, Stevens W. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol. Biotechnol. 32, 101-110 (2006).
69. Rekhviashvili N, Stevens W, Marinda E et al. Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX™ primer for quantitation of human immunodeficiency virus type-1 (HIV-1). J. Virol. Methods 146(1-2), 14-21 (2007).
70. Saha BK, Tian BH, Bucy RP. Quantitation of HIV-1 by real-time PCR with a unique fluorogenic probe. J. Virol. Methods 93(1-2), 33-42 (2001).
71. Muller J, Eis Hubinger AM, Daumer M et al. A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region. J. Virol. Methods 142(1-2), 127-135 (2007).
72. de Baar MP, van Dooren MW, De Rooij E et al. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J. Clin. Microbiol. 39, 1378-1384 (2001).
73. Candotti D, Temple J, Owusu Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J. Virol. Methods 118(1), 39-47 (2004).
74. Drosten C, Panning M, Drexler JF et al. Ultrasensitive monitoring of HIV-I viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin. Chem. 52(7), 1258-1266 (2006). • Significant paper studying the impact of HIV-1 genetic diversity on HIV-1 RNA quantification by using an in-house real-time PCR assay, in comparison with licensed HIV-1 RNA assays.
75. Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43, 2709-2717 (2005). • First demonstration of real-time PCR technology for HIV-1 monitoring and diagnosis in a resource-limited country.
76. Rouet F, Chaix ML, Nerrienet E et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction. J. Acquir. Immune Defic. Syndr. 45, 380-388 (2007).
77. Schvachsa N, Turk G, Burgard M et al. Examination of real-time PCR for HIV-1 RNA and DNA quantitation in patients infected with HIV-1BF intersubtype recombinant variants. J. Virol. Methods 140(1-2), 222-227 (2007).
78. Steegen K, Luchters S, De Cabooter N et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J. Virol. Methods 146, 178-187 (2007).
79. Holmes H, Davis G, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J. Virol. Methods 92(2), 141-150 (2001).
80. Davis C, Heath A, Best S et al. Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st international standard for HIV-1 RNA. J. Virol. Methods 107, 37-44 (2003).
81. Preiser W, Drexler JF, Drosten C. HIV-1 viral load assays for resource-limited settings: clades matter. PLoS Med. 3, e538 (2006).
82. Dabis F, Bequet L, Ekouevi DK et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19, 309-318 (2005).
83. Rouet F, Fassinou P, Inwoley A et al. Long-term survival and immunovirological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20(18), 2315-2319 (2006).
84. Chaix M-L, Ekouevi Koumavi D, Rouet F et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA DITRAME Plus, Abidjan, Côte d'Ivoire. J. Infect. Dis. 193, 482-487 (2006).
85. Chaix ML, Ekouevi DK, Peytavin G et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob. Agents Chemother. 51(3), 896-901 (2007).
86. Danel C, Moh R, Anzian A et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J. Acquir. Immune Defic. Syndr. 42(1), 29-35 (2006).
87. Danel C, Moh R, Minga A et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367(9527), 1981-1989 (2006).
88. Tonwe-Gold B, Ekouevi DK, Viho I et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 4, e257 (2007).
89. Seyler C, Adje Toure C, Messou E et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 21(9), 1157-1164 (2007).
90. Nagot N, Ouedraogo A, Foulongne V et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356(8), 790-799 (2007).
91. Janssens B, Raleigh B, Soeung S et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 120(5), E1134-E1140 (2007).
92. Ferradini L, Laureillard D, Prak N et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 21, 2293-2301 (2007).
93. Espy MJ, Uhl JR, Sloan LM et al. Real-time PCR in clinical microbiology: applications for a routine laboratory testing. Clin. Microbiol. Rev. 19(1), 165-256 (2006).
94. de Arellano ER, Martin C, Soriano V, Alcami J, Holguin A. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. Virus Genes 34(2), 111-116 (2007).
95. de Baar MP, Abebe A, Kliphuis A et al. HIV type 1 C and C' subclusters based on long terminal repeat sequences in the Ethiopian HIV type 1 subtype C epidemic. AIDS Res. Hum. Retrovirus 19, 917-922 (2003).
96. van Opijnen T, Jeeninga RE, Boerlijst MC et al. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 78, 3675-3683 (2004).
97. Khodakov DA, Zakharova NV, Gryadunov DA et al. An oligonucleotide microarray for multiplex real-time PCR identification of HIV-1, HBV, and HCV. Biotechniques 44, 241-248 (2008).
98. Plantier JC, Dachraoui R, Lemee V et al. HIV-1 resistance genotyping on dried serum spots. AIDS 19(4), 391-397 (2005).
99. Waters L, Kambugu A, Tibenderana H et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J. Acq. Immune Defic. Syndr. 46, 590-593 (2007).
100. Ou C-Y, Yang H, Balinandi S et al. Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon. J. Virol. Methods 144, 109-114 (2007).
101. Bland RM, Little KE, Coovadia HM et al. Intervention to promote exclusive breast-feeding for the first 6 months of life in a high HIV prevalence area. AIDS 22, 883-891 (2008).
102. Damond F, Roquebert B, Benard A et al. HIV-1 plasma viral load discrepancies between the Roche Cobas Amplicor HIV-1 monitor v1.5 and Roche Cobas Ampliprep/Cobas TaqMan HIV-1 assays. J. Clin. Microbiol. 45, 3436-3438 (2007).
103. Gottesman BS, Grossman Z, Lorber M et al. Comparative performance of the amplicor HIV-1 monitor assay versus NucliSens EasyQ in HIV subtype C-infected patients. J. Med. Virol. 78(7), 883-887 (2006).
104. Gene-Quantification.com & Gene-Quantification.info - The reference in qPCR - Academic & Industrial Information Platform www.gene-quantification. info